Shandong Xinhua Pharmaceutical Co Ltd

Shandong Xinhua Pharmaceutical Co Ltd has a market capitalization of $120.51 million and a price-to-earnings ratio of 4.16, indicating a relatively low valuation compared to earnings. The company's price-to-book ratio is 0.23, suggesting that the market values the company at a significant discount to its book value. The enterprise value to EBITDA ratio is 7.45, and the enterprise value to revenue ratio is 0.31, both of which are metrics commonly used in the pharmaceutical industry to assess valuation.

The company's profitability is reflected in its return on equity of 5.57% and return on assets of 3.16%, which are below the industry median for pharmaceutical companies. The gross profit margin is 18.23%, and the operating margin is 4.14%, indicating that the company is generating modest operating profits relative to its revenue. These metrics suggest that the company is not outperforming its peers in terms of profitability.

Shandong Xinhua Pharmaceutical Co Ltd's revenue is primarily concentrated in China, with no significant geographic diversification reported in the available data. The company does not disclose segment-specific revenue figures, making it difficult to assess the contribution of different product lines or geographic regions to overall performance. This lack of diversification could expose the company to regional economic or regulatory risks.

The company's revenue growth is expected to remain stable, with no significant changes projected in the current or next fiscal year. The company's historical revenue growth has been moderate, and there are no indications of a significant acceleration in the near term. The company's capital expenditures and research and development spending are not disclosed in the available data, making it difficult to assess its investment in future growth.

The company's liquidity is rated as medium, with a current ratio of 1.43, indicating that it has sufficient current assets to cover its current liabilities. However, the company has a negative net cash position after subtracting total debt, which could pose a liquidity risk if cash flow from operations is insufficient to meet short-term obligations. The dilution risk is rated as low, with no significant dilution expected in the near term.

Recent events and filings do not indicate any material changes in the company's operations or financial position. The company has not disclosed any significant new products, partnerships, or regulatory challenges that could impact its future performance. The lack of recent disclosures suggests that the company is operating in a stable environment, but it also limits the visibility into its strategic direction.